Vontobel Holding Ltd. Decreases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Vontobel Holding Ltd. decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 60.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,984 shares of the company's stock after selling 4,535 shares during the period. Vontobel Holding Ltd.'s holdings in Krystal Biotech were worth $467,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of KRYS. Summit Trail Advisors LLC bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $1,893,000. Entropy Technologies LP bought a new stake in shares of Krystal Biotech during the 4th quarter valued at about $548,000. Swiss National Bank grew its stake in shares of Krystal Biotech by 8.0% during the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $7,117,000 after purchasing an additional 2,900 shares during the period. Janney Montgomery Scott LLC grew its stake in shares of Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after purchasing an additional 15,545 shares during the period. Finally, Citigroup Inc. grew its stake in shares of Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company's stock valued at $6,386,000 after acquiring an additional 13,874 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Trading Up 2.9 %

Shares of KRYS traded up $5.24 during mid-day trading on Friday, hitting $187.86. The company's stock had a trading volume of 293,600 shares, compared to its average volume of 260,850. The company's 50-day moving average is $157.37 and its 200-day moving average is $175.23. Krystal Biotech, Inc. has a 52-week low of $107.50 and a 52-week high of $219.34. The firm has a market capitalization of $5.40 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. During the same quarter in the prior year, the company earned $0.30 EPS. The company's revenue was up 116.4% compared to the same quarter last year. As a group, sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 14.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

KRYS has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday. Chardan Capital boosted their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday. Finally, Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $210.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).